Short answer
CYTOKINETICS INC (CYTK) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
CYTOKINETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management disclosures available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $47.6M, including $44.5M MYQORZO sales, signals commercial launch traction versus $1.9M total revenue in Q3 2025
- MYQORZO adoption reached nearly 1,100 prescribers and over 2,800 dispensed patients, supporting continued U.S. growth and international expansion
- ACACIA-HCM results support planned supplemental NDA filing for non-obstructive HCM in Q4 2026 and EU Type II variation in early 2027
- Net loss narrowed to $190.1M, or $1.37 per share, from $306.2M, despite SG&A rising to $113.1M for launch investments
- Cash, equivalents and investments approximately $1.6B at September 30, 2026, while full-year combined R&D and SG&A guidance remains $860M-$890M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CYTOKINETICS INC 8-K filings
Get the next CYTK 8-K as it lands
Follow CYTK for push alerts, or ask the research agent what this filing means.